Altogether, these results suggest the immunostimulatory potential of bortezomib to augment the strength of convergent signals from CD8+T cell signaling molecules such as TCR, IL-2, IL-12 and IL-15 cytokine receptors and downstream PI3K/Akt/STAT5 pathways to sustain the expression of CD8+T cell effector molecules in the tumor microenvironment as illustrated schematically in Figure 11. This evidence concerns the gene CD8A and neoplasm.